Long‐term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of dermatology (Print)

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/1346-8138.13310PMID 26893187
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Five‐year efficacy of finasteride in 801 Japanese men with androgenetic alopecia

  2015cited by this paper
• Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis

  2014cited by this paper
• The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit–risk assessment of finasteride and dutasteride

  2014cited by this paper
• Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride

  2014cited by this paper
• A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.

  2014cited by this paper
• Systematic review evaluating cardiovascular events of the 5‐alpha reductase inhibitor – Dutasteride

  2013cited by this paper
• Persistent sexual side effects of finasteride: could they be permanent?

  2012cited by this paper
• Characteristics of Androgenetic Alopecia in Asian

  2012cited by this paper
• Quality of Life Assessment in Male Patients with Androgenetic Alopecia: Result of a Prospective, Multicenter Study

  2012cited by this paper
• The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.

  2011cited by this paper
• Male androgenetic alopecia

  2010cited by this paper
• Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.

  2010cited by this paper
• Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?

  2007cited by this paper
• 5 alpha-reductase type 2 is constitutively expressed in the dermal papilla and connective tissue sheath of the hair follicle in vivo but not during culture in vitro.

  2001cited by this paper
• Predominance of type I 5α‐reductase in apocrine sweat glands of patients with excessive or abnormal odour derived from apocrine sweat (osmidrosis)

  1998cited by this paper
• Effects of Self-Perceived Hair Loss in a Community Sample of Men

  1998cited by this paper
• The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders.

  1996cited by this paper
• Brief Male Sexual Function Inventory for urology.

  1996cited by this paper
• Androgen metabolism as it affects hair growth in androgenetic alopecia.

  1996cited by this paper
• A brief male sexual function inventory for urology.

  1995cited by this paper
• Disorders of hair growth : diagnosis and treatment

  1994cited by this paper
• Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use

  1994cited by this paper
• Male Pattern Baldness: classification and Incidence

  1975cited by this paper

• Signal detection between 5-alpha reductase inhibitors and the risk of suicidality and depression: an international pharmacovigilance analysis

  2025cites this paper
• Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial

  2025influential citation
• Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study.

  2025cites this paper
• Human‐Centric, Three Dimensional Micro Light‐Emitting Diodes for Cosmetic and Medical Phototherapy

  2025cites this paper
• Wirkstoffe effizient applizieren

  2025cites this paper
• Effectiveness and Safety of Combined Therapy with Oral Minoxidil, Oral Dutasteride, and Mesotherapy with Dutasteride in Real Clinical Practice

  2025cites this paper
• Mechanisms and clinical progress of adipose-derived stem cells and their derivatives in the treatment of hair loss

  2025cites this paper
• Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review

  2024influential citation
• Management of androgenic alopecia: a systematic review of the literature

  2024influential citation
• Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review

  2024cites this paper
• Topical dutasteride for androgenic alopecia: current state and prospects.

  2024cites this paper
• Long‐term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5‐year data demonstrating clinical improvement with sustained efficacy

  2024cites this paper
• Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs

  2023influential citation
• Evaluation of the therapeutic effects of AGA drugs by measuring finasteride, dutasteride, and dihydrotestosterone in hair.

  2023cites this paper
• Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study

  2023cites this paper
• POST-FINASTERIDE SYNDROME AND POST-SSRI SEXUAL DYSFUNCTION: TWO CLINICAL CONDITIONS APPARENTLY DISTANT, BUT VERY CLOSE.

  2023cites this paper
• Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects

  2023cites this paper
• Nanotechnology-based techniques for hair follicle regeneration.

  2023cites this paper
• Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study

  2022cites this paper
• Identification of Beta-Sitosterol and Stigmasterol as Possible Inhibitors of 5 Alpha-Reductase 1: An In-Silico Study

  2022cites this paper
• Pharmacotherapy of androgenetic alopecia – a literature review

  2022cites this paper
• Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia

  2022cites this paper
• Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target

  2021cites this paper
• Hair Transplantation: Basic Overview.

  2021cites this paper
• Hair Transplantation Surgery Versus Other Modalities of Treatment in Androgenetic Alopecia: A Narrative Review

  2021cites this paper
• Bioactive lead compounds and molecular targets for the treatment of heart disease.Phytochemicals as Lead Compounds for New Drug Discoverys

  2020cites this paper
• Post-finasteride syndrome: a surmountable challenge for clinicians.

  2020cites this paper
• Low-level laser therapy and narrative review of other treatment modalities in androgenetic alopecia

  2020cites this paper
• Phytochemicals as emerging therapeutic agents for alopecia treatment

  2020cites this paper
• A review of the treatment of male pattern hair loss

  2020cites this paper
• Efficacy of Intralesional and Oral Dutasteride in the Treatment of Androgenetic Alopecia: A Systematic Review

  2020cites this paper
• Post-finasteride syndrome: An emerging clinical problem

  2019cites this paper
• Post-finasteride syndrome – does it really exist?

  2019cites this paper
• Guidelines for the diagnosis and treatment of male‐pattern and female‐pattern hair loss, 2017 version

  2018cites this paper
• What do we know about 5-alpha reductase inhibitors ?

  2018cites this paper
• The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption

  2018cites this paper
• Dermatology today and tomorrow: from symptom control to targeted therapy

  2018cites this paper
• Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study.

  2018cites this paper
• Nanotechnology advances for hair loss.

  2018cites this paper
• The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model

  2018cites this paper
• Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study

  2018cites this paper
• Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia

  2018cites this paper
• Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction

  2017cites this paper
• Novedades terapéuticas en tricología

  2017cites this paper
• Therapeutic Considerations Related to Finasteride Administration in Male Androgenic Alopecia and Benign Prostatic Hyperplasia

  2017cites this paper
• The Effect of Smoking on Facial Aging Among Females in Saudi Arabia

  2017cites this paper
• Long‐term efficacy and safety of the dual 5‐alpha reductase blocker dutasteride on male androgenetic alopecia patients

  2017cites this paper
• Addressing androgenetic alopecia–a complex disorder–with a multilateral treatment strategy

  2017cites this paper
• Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia

  2017cites this paper
• Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride

  2017cites this paper
• New Treatments for Hair Loss.

  2017cites this paper
• Dutasteride in Androgenetic Alopecia: An Update.

  2017cites this paper
• Multi‐therapies in androgenetic alopecia: review and clinical experiences

  2016cites this paper
• The postfinasteride syndrome; an overview

  2016cites this paper
• Current Advances in the Treatment of Androgenic Hair Loss

  year unknowncites this paper
• NOVELTIES IN DERMATOLOGY New Treatments for Hair Loss (cid:2)

  year unknowncites this paper